Clinical Trial Update: Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating liraglutide 3 mg (Saxenda) effects on weight, body composition, hormonal and metabolic parameters in obese women with PCOS; study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Polycystic Ovary Syndrome

Drugs mentioned

• liraglutide 3 mg (liraglutide)

Snippet

Sponsor: Woman's | Conditions: Pre Diabetes, Polycystic Ovary Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2021-06-07